173 related articles for article (PubMed ID: 34522267)
1. Vildagliptin, a dipeptidyl peptidase-4 inhibitor, attenuated endothelial dysfunction through miRNAs in diabetic rats.
Zhang Q; Xiao X; Zheng J; Li M; Yu M; Ping F; Wang T; Wang X
Arch Med Sci; 2021; 17(5):1378-1387. PubMed ID: 34522267
[TBL] [Abstract][Full Text] [Related]
2. A Possible Mechanism: Vildagliptin Prevents Aortic Dysfunction through Paraoxonase and Angiopoietin-Like 3.
Zhang Q; Xiao X; Zheng J; Li M; Yu M; Ping F; Wang T; Wang X
Biomed Res Int; 2018; 2018():3109251. PubMed ID: 29951533
[TBL] [Abstract][Full Text] [Related]
3. A glucagon-like peptide-1 analog, liraglutide, ameliorates endothelial dysfunction through miRNAs to inhibit apoptosis in rats.
Zhang Q; Xiao X; Zheng J; Li M
PeerJ; 2019; 7():e6567. PubMed ID: 30863684
[TBL] [Abstract][Full Text] [Related]
4. Activation of Transient Receptor Potential Channel Vanilloid 4 by DPP-4 (Dipeptidyl Peptidase-4) Inhibitor Vildagliptin Protects Against Diabetic Endothelial Dysfunction.
Gao P; Li L; Wei X; Wang M; Hong Y; Wu H; Shen Y; Ma T; Wei X; Zhang Q; Fang X; Wang L; Yan Z; Du GH; Zheng H; Yang G; Liu D; Zhu Z
Hypertension; 2020 Jan; 75(1):150-162. PubMed ID: 31735085
[TBL] [Abstract][Full Text] [Related]
5. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S
Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107
[TBL] [Abstract][Full Text] [Related]
6. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice.
Terasaki M; Nagashima M; Nohtomi K; Kohashi K; Tomoyasu M; Sinmura K; Nogi Y; Katayama Y; Sato K; Itoh F; Watanabe T; Hirano T
PLoS One; 2013; 8(8):e70933. PubMed ID: 23967137
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitor enhances restoration of salivary glands impaired by obese-insulin resistance.
Ittichaicharoen J; Apaijai N; Tanajak P; Sa-Nguanmoo P; Chattipakorn N; Chattipakorn S
Arch Oral Biol; 2018 Jan; 85():148-153. PubMed ID: 29073562
[TBL] [Abstract][Full Text] [Related]
8. Favorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic rats.
El Batsh MM; El Batch MM; Shafik NM; Younos IH
Eur J Pharmacol; 2015 Dec; 769():297-305. PubMed ID: 26607467
[TBL] [Abstract][Full Text] [Related]
9. miR-448-3p alleviates diabetic vascular dysfunction by inhibiting endothelial-mesenchymal transition through DPP-4 dysregulation.
Guan GY; Wei N; Song T; Zhao C; Sun Y; Pan RX; Zhang LL; Xu YY; Dai YM; Han H
J Cell Physiol; 2020 Dec; 235(12):10024-10036. PubMed ID: 32542696
[TBL] [Abstract][Full Text] [Related]
10. A dipeptidyl peptidase-IV inhibitor improves diastolic dysfunction in Dahl salt-sensitive rats.
Nakajima Y; Ito S; Asakura M; Min KD; Fu HY; Imazu M; Hitsumoto T; Takahama H; Shindo K; Fukuda H; Yamazaki S; Asanuma H; Kitakaze M
J Mol Cell Cardiol; 2019 Apr; 129():257-265. PubMed ID: 30880253
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.
Inthachai T; Lekawanvijit S; Kumfu S; Apaijai N; Pongkan W; Chattipakorn SC; Chattipakorn N
Exp Physiol; 2015 Jun; 100(6):667-79. PubMed ID: 25823534
[TBL] [Abstract][Full Text] [Related]
12. Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice.
Aini K; Fukuda D; Tanaka K; Higashikuni Y; Hirata Y; Yagi S; Kusunose K; Yamada H; Soeki T; Sata M
Int Heart J; 2019 Nov; 60(6):1421-1429. PubMed ID: 31735774
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.
Tang ST; Su H; Zhang Q; Tang HQ; Wang CJ; Zhou Q; Wei W; Zhu HQ; Wang Y
Int J Mol Med; 2016 Jun; 37(6):1558-66. PubMed ID: 27122056
[TBL] [Abstract][Full Text] [Related]
14. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats.
Zhang Q; Xiao X; Li M; Yu M; Ping F; Zheng J; Wang T; Wang X
PLoS One; 2017; 12(10):e0184735. PubMed ID: 29036231
[TBL] [Abstract][Full Text] [Related]
15. Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor κB signaling pathways.
Tang ST; Zhang Q; Tang HQ; Wang CJ; Su H; Zhou Q; Wei W; Zhu HQ; Wang Y
Endocrine; 2016 Jul; 53(1):107-16. PubMed ID: 26758998
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice.
Takahashi A; Asakura M; Ito S; Min KD; Shindo K; Yan Y; Liao Y; Yamazaki S; Sanada S; Asano Y; Ishibashi-Ueda H; Takashima S; Minamino T; Asanuma H; Mochizuki N; Kitakaze M
Am J Physiol Heart Circ Physiol; 2013 May; 304(10):H1361-9. PubMed ID: 23504176
[TBL] [Abstract][Full Text] [Related]
17. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
[TBL] [Abstract][Full Text] [Related]
18. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
Jin HY; Liu WJ; Park JH; Baek HS; Park TS
Arch Med Res; 2009 Oct; 40(7):536-44. PubMed ID: 20082866
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats.
Maeda S; Yamagishi S; Matsui T; Nakashima S; Ojima A; Maeda S; Nishino Y; Ishibashi Y; Yoshida Y; Yamakawa R
Ophthalmic Res; 2013; 50(4):221-6. PubMed ID: 24081217
[TBL] [Abstract][Full Text] [Related]
20. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
